Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.
Epistemonikos ID: 5212deec9009c0f1b13300c3e53969ff08476ef6
First added on: May 09, 2024